Advertisement
Skip to Content

Editas Medicine Inc EDIT Stock Quote

| Rating as of

NASDAQ: EDIT

Last close prices updated as of Jan 30, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 9.35
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Blend
  • Day Range 9.02  –  9.53
  • Year Range 7.71  –  21.60
  • Market Cap 642.9337 Mil
  • Volume / Avg 1.9 Mil /  2.0 Mil
  • Price / Sales 25.00
  • Price / Book 1.55
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis EDIT

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics EDIT

Company Profile EDIT

Business Description

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.

Contact
11 Hurley Street
Cambridge, MA, 02141
Industry Biotechnology
Employees 264

Related Articles EDIT

FAQs for Editas Medicine Inc Stock

No. EDIT does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

EDIT’s market cap is 642.93 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

EDIT’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

EDIT’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare EDIT’s historical performance against its industry peers and the overall market.